Searchable abstracts of presentations at key conferences in endocrinology

ea0077p3 | Adrenal and Cardiovascular | SFEBES2021

Improving outcomes from SSTS: Redefining Cortisol Cut-Offs

Choudhury Sirazum , Ramadoss Vijay , Lazarus Katharine , Tan Tricia , Meeran Karim

Background: Short Synacthen Tests (SSTs) are integral to the diagnosis of Adrenal Insufficiency (AI). A 30-minute stimulated cortisol value is assessed against local assay dependent thresholds to ascertain or exclude the diagnosis. A diagnosis of AI is a life changing event requiring the initiation of life long glucocorticoid replacement therapy for survival. Glucocorticoid replacement is associated with long term morbidity and mortality, including an increased risk of diabete...

ea0077p19 | Adrenal and Cardiovascular | SFEBES2021

Prednisolone versus Hydrocortisone in Adrenal Insufficiency: A positive and negative control cross-sectional study

Choudhury Sirazum , Lazarus Katharine , Thaventhiran Thilipan , Tan Tricia , Meeran Karim

Background: Management of adrenal insufficiency (AI) with glucocorticoid replacement is associated with increased mortality and morbidity. There is growing evidence that this is because of excess, non-physiological steroid exposure. Low dose prednisolone (2-4 mg) is a once-daily alternative to standard hydrocortisone regimens that more closely mimics the circadian rhythm and may translate to better outcomes. There is however a paucity of studies comparing the two treatments.</...

ea0081p530 | Adrenal and Cardiovascular Endocrinology | ECE2022

Objective markers and new indicators in adrenal insufficiency- findings from the omni-aid study comparing hydrocortisone and prednisolone replacement therapy

Choudhury Sirazum , Thaventhiran Thilipan , Lazarus Katharine , Tan Tricia , Meeran Karim

Background: Adrenal insufficiency (AI) is a life-threatening condition if left unmanaged. Despite treatment patients can expect a life expectancy that is shortened by 12 years secondary to probable inherent over-replacement associated with oral glucocorticoid regimens. Thrice-daily hydrocortisone is the most common regimen used. Very low-dose prednisolone (2-4 mg) is an alternative with lower uptake due to the absence of evidence for its use. This study fills this literature g...

ea0050p018 | Adrenal and Steroids | SFEBES2017

Prednisolone should be first line replacement therapy for adrenal insufficiency

Prabhudev Hemanth , Smith David , Choudhury Sirazum , Meeran Karim

Introduction: We offer patients needing glucocorticoid replacement in primary and secondary adrenal insufficiency the choice of either once daily prednisolone or thrice daily hydrocortisone. A recent European study found no difference between prednisolone and hydrocortisone users in several markers, including glucose, weight, body mass index (BMI), systolic and diastolic blood pressure and waist circumference, although they did suggest an increase in cholesterol and low densit...

ea0050p018 | Adrenal and Steroids | SFEBES2017

Prednisolone should be first line replacement therapy for adrenal insufficiency

Prabhudev Hemanth , Smith David , Choudhury Sirazum , Meeran Karim

Introduction: We offer patients needing glucocorticoid replacement in primary and secondary adrenal insufficiency the choice of either once daily prednisolone or thrice daily hydrocortisone. A recent European study found no difference between prednisolone and hydrocortisone users in several markers, including glucose, weight, body mass index (BMI), systolic and diastolic blood pressure and waist circumference, although they did suggest an increase in cholesterol and low densit...

ea0086p161 | Adrenal and Cardiovascular | SFEBES2022

Prednisolone replacement therapy in Adrenal Insufficiency: Defining target ranges and timing for optimum Prednisolone level sampling

Sharma Angelica , Lazarus Katharine , Choudhury Sirazum , Meeran Karim

Introduction: Glucocorticoid replacement in adrenal insufficiency may be achieved by administering thrice- daily hydrocortisone or once-daily very low dose (2-4 mg) prednisolone. Prednisolone’s longer half-life enables once-daily dosing, improving patient satisfaction and compliance. At very low doses, it has shown no difference in most markers of metabolic risk when compared with hydrocortisone. At Imperial College Healthcare NHS Trust (ICHNT), use of an eight-hour troug...

ea0086p162 | Adrenal and Cardiovascular | SFEBES2022

5mg of Prednisolone results in over-replacement in individuals with Adrenal Insufficiency

Sharma Angelica , Lazarus Katharine , Choudhury Sirazum , Meeran Karim

Introduction: Liberal glucocorticoid replacement therapy prevents Addisonian crises in individuals with adrenal insufficiency (AI). Prednisolone is six to eight times more potent than hydrocortisone. There is inter-individual variation in glucocorticoid metabolism wherein 5 mg prednisolone once-daily may result in over-replacement in most individuals, with subsequent long-term morbidity and mortality.Methods: Data from individuals on established predniso...

ea0086p95 | Neuroendocrinology and Pituitary | SFEBES2022

Optimising the Insulin Tolerance Test: Cortisol Thresholds on Abbott Platforms should be lowered to 416 nmol/L

Hayes Annabel , Choudhury Sirazum , Lazarus Katharine , Meeran Karim

Background: Adrenal insufficiency (AI) is a life-threatening condition which requires long term glucocorticoid (GC) replacement. Patient misdiagnosis results in inappropriate GC use, which has significant adverse effects and is associated with an increased mortality risk. The insulin tolerance test (ITT) is the gold standard test for diagnosis, but the widely accepted cut-off value of ≤550 nmol/l used to diagnose AI is founded on outdated immunoassays. Use of this cut-of...

ea0044p89 | Clinical biochemistry | SFEBES2016

The use of 8-h serum prednisolone concentrations to guide prednisolone dosing in replacement therapy

Papadopoulou Deborah , Choudhury Sirazum M , Meeran Karim , Wernig Florian

We here report the cases of two patients receiving glucocorticoid replacement, whose treatment has been guided by serum prednisolone measurements and whose day curves are presented below. Ms B was a 33-year-old patient who presented 3 years ago with panhypopituitarism following transsphenoidal surgery in 2012, for a sellar mass in a foreign country. She had already commenced 5mg prednisolone daily in addition to DDAVP, levothyroxine and the COCP. Having noticed mild weight gai...

ea0025p34 | Clinical biochemistry | SFEBES2011

An unusual case of leg weakness in a patient with diabetes and Addison's disease (Is there a common link?)

Platts Julia , Choudhury Maitrayee , Manning Alexis , Withenshaw Nicholas

Both diabetes and Addisons’ are conditions which can be associated with muscle weakness and altered potassium levels. This is a case of recurrent muscle paralysis in a patient with both conditions with the underlying abnormality being the neurological condition of hypokalaemic periodic paralysis.A 23-year-old Caucasian gentleman was admitted to medical admissions with sudden onset weakness of his lower legs. On examination he had reduced power of hi...